Cancer Cachexia: Its Mechanism and Clinical Significance
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The term “cachexia” is derived from the Greek words kakos (bad) and hexis (habit). Cachexia is a malnutrition associated with chronic diseases such as cancer, chronic heart failure, chronic renal failure, and autoimmune diseases, and is characterized by decreased skeletal muscle mass. Cancer cachexia is quite common in patients with advanced cancer. Weight loss is also a characteristic symptom of cancer cachexia, along with decreased skeletal muscle mass. As nutritional supplementation alone cannot improve cachexia, cytokines and tumor-derived substances have been attracting attention as its relevant factors. Cancer cachexia can be also associated with reduced chemotherapeutic effects, increased side effects and treatment interruptions, and even poorer survival. In 2011, a consensus definition of cachexia has been proposed, and the number of relevant research reports has increased significantly. However, the pathogenesis of cachexia is not fully understood, and there are currently few regulatory-approved standard treatments for cachexia. The main reason for this is that multiple etiologies are involved in the development of cachexia. In this review, we will outline the current status of cachexia, the mechanisms of which have been elucidated in recent years, especially from the perspective of advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., Baptista, G., Barazzoni, R., Blaauw, R., Coats, A., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.002 · Cited by 3,022
ESPEN guidelines on definitions and terminology of clinical nutrition
Cederholm, T., Barazzoni, R., Austin, P., Ballmer, P., Biolo, G., Bischoff, S. C., Compher, C., Correia, I., Higashiguchi, T., Holst, M., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.004 · Cited by 2,560
Muscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 4×
“Decreased skeletal muscle mass, muscle strength and function have been reported to have adverse effects on QOL and life expectancy, and have recently become widely known as sarcopenia [2,8].”
BackgroundInfluentialCederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., Baptista, G., Barazzoni, R., Blaauw, R., Coats, A. J. S., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12383 · Cited by 1,724
ESPEN practical guideline: Clinical Nutrition in cancer
Muscaritoli, M., Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Hütterer, E., Isenring, E., Kaasa, S., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.02.005 · Cited by 1,702 · cited 4×
“Therefore, the ESPEN guidelines recommend TEE to be set at 30–35 kcal/kg/day in outpatients and 20–25 kcal/kg/day in bedridden patients [32,89].”
BackgroundMethodInfluentialJensen, G. L., Cederholm, T., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., de Baptista, G. A., Barazzoni, R., Blaauw, R., Coats, A. J. S., et al. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1440 · Cited by 1,442
ESPEN expert group recommendations for action against cancer-related malnutrition
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P. C., Deutz, N. E. P., Erickson, N., Laviano, A., Lisanti, M. P., Lobo, D. N., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.017 · Cited by 1,305
SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155 · cited 1×
“This criterion is called cachexia staging score (CSS) and includes weight loss in 6 months (0–3 points), SARC-F (a screening tool for sarcopenia [25], 0–3 points), ECOG-PS (0–2 points), appetite loss (0–2 points), and abnormal biochemistry (0–2 points), and thus it consists of five items (total of 12 points) [24].”
BackgroundObesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4283 · Cited by 1,004
Akash, M. S. H., Rehman, K., & Liaqat, A. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26174 · Cited by 690
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100092 · Cited by 586
Adamsen, L., Quist, M., Andersen, C., Moller, T., Herrstedt, J., Kronborg, D., Baadsgaard, M. T., Vistisen, K., Midtgaard, J., Christiansen, B., et al. (2009) · BMJ · doi:10.1136/bmj.b3410 · Cited by 492
Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., & Cerny, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1847 · Cited by 413 · cited 1×
“Corticosteroids [96], nonsteroidal anti-inflammatory drugs [97], androgens [98], progestins [99], cannabinoids [100], and other drugs have been reported to be useful in patients with cachexia, but their efficacy was limited to improvement of QOL.”
BackgroundDobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Cheville, A. L., Kollasch, J., Vandenberg, J., Shen, T., Grothey, A., Gamble, G., & Basford, J. R. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.05.006 · Cited by 299
Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer · doi:10.1002/cncr.31128 · Cited by 239
Microbiota-modulated CART + enteric neurons autonomously regulate blood glucose
Muller, P. A., Matheis, F., Schneeberger, M., Kerner, Z., Jové, V., & Mucida, D. (2020) · Science · doi:10.1126/science.abd6176 · Cited by 154 · cited 3×
“The main components are neuropeptide Y (NPY) [58] and agouti gene-related protein (AgRP) [59], which promote appetite, and proopiomelanocortin (POMC) [60] and cocaine and amphetamine-regulated transcrip (CART) [61], which suppress appetite.”
BackgroundIncreased gut permeability in cancer cachexia: mechanisms and clinical relevance
Bindels, L. B., Neyrinck, A. M., Loumaye, A., Catry, E., Walgrave, H., Cherbuy, C., Leclercq, S., Van Hul, M., Plovier, H., Pachikian, B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24804 · Cited by 147 · cited 1×
“In cancer cachexia, increased gut permeability can promote the diffusion of proinflammatory or inflammatory molecules on the intestinal barrier, resulting in systemic inflammation [109].”
BackgroundHeywood, R., McCarthy, A. L., & Skinner, T. L. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3827-0 · Cited by 123
Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact
Nishikawa, H., Enomoto, H., Nishiguchi, S., & Iijima, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041917 · Cited by 56
Self-citation
Cited by
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions
Wang, T., Zhou, D., & Hong, Z. (2025) · MedComm · doi:10.1002/mco2.70030 · Cited by 46
Diet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Metadata
- Authors
- Nishikawa, H., Goto, M., Fukunishi, S., Asai, A., Nishiguchi, S., & Higuchi, K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-06
- Volume
- 22
- Issue
- 16
- Pages
- 8491
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3188414598
- Cited by
- 233
- References
- 24
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.